Emerging research suggest this peptide, a dual stimulator targeting both GLP-1 and GIP , may offer a promising development for obesity management . Preliminary clinical tests get more info have indicated substantial reductions in visceral tissue, possibly exceeding current obesity medications . Nevertheless , more evaluation is necessary to thoroug